Trial Profile
Phase 1/2a Open-label Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 23 Feb 2024
Price :
$35
*
At a glance
- Drugs BI 1607 (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer; Male breast cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions; First in man; Proof of concept
- Acronyms CONTRAST
- 16 Feb 2024 Planned End Date changed from 1 Dec 2026 to 1 Apr 2024.
- 16 Feb 2024 Status changed from recruiting to active, no longer recruiting.
- 09 Dec 2023 Trial design presented at the 46th Annual San Antonio Breast Cancer Symposium